Dose-response and time-course characteristics of UV-A1 erythema

Archives of Dermatology

Volumn 141, Issue 12, 2005, Pages 1549-1555

  Beattie, Paula E ^a   Dawe, Robert S ^a   Ferguson, James ^a   Ibbotson, Sally H ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARM; ARTICLE; BACK; CLASSIFICATION; CLINICAL ARTICLE; CONTROLLED STUDY; ERYTHEMA; HUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIATION EXPOSURE; REACTION TIME; RISK ASSESSMENT; SCORING SYSTEM; SKIN; ULTRAVIOLET A RADIATION; UNIVERSITY HOSPITAL; VISUAL ANALOG SCALE;

ADULT; ARM; BACK; DOSE-RESPONSE RELATIONSHIP, RADIATION; ERYTHEMA; HOSPITALS, UNIVERSITY; HUMANS; MIDDLE AGED; SCOTLAND; SKIN PIGMENTATION; TIME FACTORS; ULTRAVIOLET RAYS;

EID: 29144443065     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.141.12.1549     Document Type: Article

References (29)

1. Melski JW, Tanenbaum L, Parrish JA, Fitzpatrick TB, Bleich HL. Oral methoxsalen photochemotherapy for the treatment of psoriasis: a cooperative clinical trial. J Invest Dermatol. 1977;68:328-335.
2. Seité S, Verdier MP, Hourseau C, Fourtanier A. Accumulated p53 protein and UVA protection level of sunscreens. Photodermatol Photoimmunol Photomed. 2000;16:3-9.
3. Jekler J, Larkö O. Phototherapy for atopic dermatitis with ultraviolet A (UVA), low dose UVB and combined UVA and UVB: two paired-comparison studies. Photodermatol Photoimmunol Photomed. 1991;8:151-156.
4. Grabbe J, Welker P, Humke S, et al. High-dose ultraviolet A1 (UVA1), but not UVA/UVB therapy, decreases IgE-binding cells in lesional skin of patients with atopic eczema. J Invest Dermatol. 1996;197:419-422.
5. Tzaneva S, Seber A, Schwaiger M, Honigsmann H, Tanew A. High-dose versus medium-dose UVA1 phototherapy for patients with severe generalized atopic dermatitis. J Am Acad Dermatol. 2001;45:503-507.
6. Breuckmann F, von Koyyletzki G, Avermaete A, Kreuter A, Altmeyer P. Efficacy of ultraviolet A1 phototherapy on the expression of bcl-2 in atopic dermatitis and cutaneous T-cell lymphoma in vivo: a comparison study. Photodermatol Photoimmunol Photomed. 2002;18:217-222.
7. Petersen M, Hansen C, Craig C. Ultraviolet A irradiation stimulates collagenase production in cultured human fibroblasts. J Invest Dermatol. 1992;99:440-444.
8. Mempel M, Schmidt T, Boeck K, et al. Changes in collagen I and collagen III metabolism in patients with generalised atopic eczema undergoing medium-dose ultraviolet A1 phototherapy. Br J Dermatol. 2000;142:473-480.
9. Yin L, Yamauchi R, Tsuji T, Krutmann J, Morita A. The expression of matrix metalloproteinase-1 mRNA induced by ultraviolet A1 (340-400nm) phototherapy is relevant to the glutathione (GSH) content in skin fibroblasts of systemic sclerosis. J Dermatol. 2003;30:173-180.
10. Kerscher M, Dirschka T, Volkenandt M. Treatment of localised scleroderma by UVA1 phototherapy [letter]. Lancet. 1995;346:1166.
11. Von Kobyletzki G, Pieck C, Hoffman K, Freitag M, Altmeyer P. Medium-dose UVA1 cold-light phototherapy in the treatment of severe atopic dermatitis. J Am Acad Dermatol. 1999;41:931-937.
12. Krutmann J, Schöpf E. High dose UVA1 phototherapy: a novel and highly effective approach for the treatment of acute exacerbation of atopic dermatitis. Acta Derm Venereol Suppl (Stockh). 1992;176:120-122.
13. Krutmann J, Czech W, Diepgen T, Niedner R, Kapp A, Schopf E. High-dose UVA1 therapy in the treatment of patients with atopic dermatitis. J Am Acad Dermatol. 1992;26:225-230.
14. Krutmann J, Diepgen TL, Luger TA, et al. High dose UVA1 therapy for atopic dermatitis: results of a multi-centre trial. J Am Acad Dermatol. 1998;38:589-593.
15. Dittmar HC, Pflieger D, Schöpf E, Simon JC. UVA1 phototherapy: pilot study of dose finding in acute exacerbated atopic dermatitis. Hautarzt. 2001;52:423-427.
16. Morita A, Kobayashi K, Isomura I, Tsuji T, Krutmann J. Ultraviolet A1 (340-400nm) phototherapy for scleroderma in systemic sclerosis. J Am Acad Dermatol. 2000;43:670-674.
17. Stege H, Berenburg M, Humke S, et al. High dose UVA1 radiation therapy for localised scleroderma. J Am Acad Dermatol. 1997;36:938-944.
18. Hannuksela-Svahn A, Grandal OJ, Thornstein T, Christensen OB. UVA1 for treatment of keloids [letter]. Acta Derm Venereol. 1999;79:490.
19. Stege H, Schöpf E, Ruzicka T, Krutmann J. High dose UVA1 for urticaria pigmentosa [letter]. Lancet. 1996;347:64.
20. Zane C, Leali C, Airo P, De Panfilis G, Pinton PC. "High dose" UVA1 therapy of widespread plaque type, nodular, and erythrodermic mycosis fungoides. J Am Acad Dermatol. 2001;44:629-633.
21. Plotz SG, Abeck D, Seitzer U, Hein R, Ring J. UVA1 for hypereosinophilic syndrome [letter]. Acta Derm Venereol. 2000;80:221.
22. Su RC, Chong LY, Lo KK. High dose UVA1 radiation therapy for localised scleroderma. J Am Acad Dermatol. 1998;39:517-518.
23. Diffey B, Oliver R, Farr P. A portable instrument for quantifying erythema induced by ultraviolet radiation. Br J Dermatol. 1984;111:663-672.
24. Man I, Dawe RS, Ferguson J, Ibbotson SH. The time course of TL0-1 erythema [abstract]. Photodermatol Photoimmunol Photomed. 2002;18:105.
25. Man I, McKinlay J, Dawe RS, Ferguson J, Ibbotson SH. An intraindividual comparative study of psoralen-UVA erythema induced by bath 8-methoxypsoralen and 4, 5′, 8-trimethylpsoralen. J Am Acad Dermatol. 2003;49:59-64.
26. Davidson A. Calculation of erythema dose-response curves using a spreadsheet. Photodermatol Photoimmunol Photomed. 1999;15:104-108.
27. Sakuntabhai A, Farr PM, Diffey BL. PUVA erythemal sensitivity depends on plasma psoralen concentration and UVA sensitivity. Br J Dermatol. 1993;128:561-565.
28. Cox NH, Farr PM, Diffey BL. A comparison of the dose-response relationship for psoralen-UVA erythema and UVB erythema. Arch Dermatol. 1989;125:1653-1657.
29. Man I, Dawe RS, Ferguson J, Ibbotson SH. An intraindividual study on the characteristics of erythema induced by bath and oral methoxsalen photochemotherapy and narrowband ultraviolet B. Photochem Photobiol. 2003;78:55-60.